SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-210800
Filing Date
2023-08-11
Accepted
2023-08-11 16:30:44
Documents
12
Period of Report
2023-08-09
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d477277d8k.htm   iXBRL 8-K 26079
  Complete submission text file 0001193125-23-210800.txt   144140

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syrs-20230809.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20230809_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20230809_pre.xml EX-101.PRE 10809
6 EXTRACTED XBRL INSTANCE DOCUMENT d477277d8k_htm.xml XML 3226
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 231164574
SIC: 2834 Pharmaceutical Preparations